477 Three Dimensional Imaging of Multiple AAV Serotype/Mutant Vector Transductions in the Non Human Primate Brain By Massively Parallel Sequencing Molecular Therapy Volume 23, Supplement 1, May 2015 C[.]
Trang 1Molecular Therapy Volume 23, Supplement 1, May 2015
Copyright © The American Society of Gene & Cell Therapy S189
Presidential symPosium
mutation in 3 pts), 8 pts (29%) had prior allogeneic stem cell transplant
(allo-SCT), and 22 pts (78%) had either primary refractory disease
or CR1 duration of <12 months Of the 28 pts, 27 pts were evaluable
for response At the time of 19-28z CAR T cell infusion, 14 of 27
evaluable pts had morphologic disease (>5% blasts in BM) and 13
pts had minimal residual disease (MRD) 24 of 27 pts (89%) were in
complete remission (CR) following the 19-28z CAR T cell infusion;
11 of these pts had morphologic disease at the time of T cell infusion,
and 13 pts had MRD 21 of 24 CR (88%) was MRD negative A
median time to CR was 22.5 days (range, 9-33) 10 pts successfully
underwent allo-HSCT following the 19-28z CAR T cell therapy
The median follow-up is 6 months (range, 1-38 months) with 15 pts
having at least 6 months of follow-up Responses appear durable with
12 pts remaining disease-free, including 7 pts without subsequent
allo-SCT Median OS of all pts is 8.5 months While none of the 13
pts with MRD at the time of T cell infusion developed significant
cytokine release syndrome (CRS), 5 of 15 pts with morphologic
disease developed severe CRS that required either vasopressors
or mechanical ventilation for hypoxia, successfully managed with
corticosteroid and/or IL-6R inhibitor
Conclusion: Treatment with 19-28z CAR T cells can induce a high
CR rate of 89% in these heavily pretreated adult pts with R/R ALL
regardless of the disease risk characteristics including Ph+ status,
age, pre-T cell disease burden, prior allo-SCT, and CR1 duration
While CRS can develop following T cell infusion, the risk of CRS
predictably correlates with the disease burden and can successfully be
managed with corticosteroid and/or IL-6R inhibitor These findings
support the use of 19-28z CAR T cells in adult pts with R/R ALL and
warrant a further investigation in a larger phase 2 trial
476 Clonal Tracking of Engineered
Hematopoiesis In Vivo in Humans By Insertional
Barcoding
Luca Biasco,1 Francesca Dionisio,1 Danilo Pellin,2 Serena Scala,1,3
Luca Basso Ricci,1 Samantha Scaramuzza,1 Cristina Baricordi,1
Andrea Calabria,1 Stefania Giannelli,1 Victor Neduva,4 David
J Dow,4 Eugenio Montini,1 Clelia Di Serio,2,3 Luigi Naldini,1
Alessandro Aiuti.1,3
1 San Raffaele Telethon Institute for Gene Therapy (TIGET), Milan,
Italy; 2 CUSSB, Univ Vita-Salute San Raffaele, Milan, Italy;
3 Univ Vita-Salute San Raffaele, Milan, Italy; 4 Molecular and
Cellular Technologies, GlaxoSmithKline, Stevenage Herts, United
Kingdom; 5 Univ degli studi Roma Tre, Rome, Italy.
Upon gene therapy (GT) for adenosine deaminase (ADA)
deficient-SCID and Wiskott-Aldrich Syndrome (WAS), gene-corrected
hematopoietic stem/progenitor cells (HSPC) generated a stable
genetically engineered hematopoietic system where each
vector-marked cell is univocally barcoded by a vector integration site (IS)
To study the dynamics of human hematopoietic system, we collected
by LAM-PCR+Illumina sequencing 28.539.414 sequence reads
corresponding to 89.373 IS tagging clones belonging to 13 different
cell types purified from the bone marrow and the peripheral blood
of 4 WAS patients up to 48 months after GT We firstly identified
identical IS shared among CD34+ progenitors, and mature Myeloid/
Lymphoid cells as markers of the real-time clonal output of
vector-marked HSPC clones in vivo We unraveled the nature and timing
of short, intermediate and long term HSPC output showing that
CD34+ clones active at 3-6 months after GT are not detectable at later
follow up Distinct waves of HSPC diversity were observed during
the first 6-9 months after GT reaching a homeostatic equilibrium
only by 12 months By unsupervised clustering of IS similarities
among lineages we unveiled diverse HSPC output towards lymphoid,
myeloid and megakaryo-erythroid cells showing hints of a NK cells
origin distinct from T and B cells We exploited IS similarities to
infere and test hematopoietic hierarchies by combining conditional probability distributions and static/dynamic graphical models of dependencies We also estimated by mark-recapture approaches that just few thousands clones (1185-2884) are responsible for the long-term maintenance of the whole genetically engineered hematopoietic system The ongoing analyses on IS collected from 7 distinct CD34+ subtypes isolated from GT patients will further increase HSPC tracking resolution To evaluate the preservation of activity
by transplanted HSPC we exploited data derived from the IS-based tracking of 4.845 clones in ADA-SCID patients performed for up to 6 years after GT We showed that identical IS are consistently detected
at multiple lineages level even several years after GT Strikingly,
by semi-quantitative PCRs on specific vector-genome junctions we tracked a fluctuating but consistent output of marked HSPC over
a period of 5 years without the manifestation of clonal quiescence phases Since gamma-retroviral vector used in this GT trial actively transduce only replicating cells, this provide the first evidence that HSPC, awaken from dormancy in vitro, can still retain in vivo long-term activity Overall our work constitute the first molecular tracking
of hematopoietic system in humans The information gathered are crucial for the design of therapeutic approaches for a broad spectrum
of hematological diseases and tumors
477 Three-Dimensional Imaging of Multiple AAV Serotype/Mutant Vector Transductions in the Non-Human Primate Brain By Massively Parallel Sequencing
Kei Adachi,1 Zheng Liu,1,2 Christopher D Kroenke,1,2 Gregory A Dissen,2 Sergio R Ojeda,2 Hiroyuki Nakai.1
1 Oregon Health and Science University, Portland, OR; 2 Oregon Health and Science University, Oregon National Primate Research Center, Beaverton, OR.
Global therapeutic gene delivery to the central nervous system (CNS) offers a promising approach to treat CNS diseases and preclinical studies using rodents have shown AAV9 as a potential candidate to achieve this goal However, recent work has highlighted the existence of nonhuman primate (NHP)-rodent differences in AAV vector biology and transduction profiles in the CNS after gene delivery, making imperative a more rigorous evaluation of various AAV serotype and capsid mutant vectors in NHPs It is of particular importance to understand how each AAV strain (serotype
or mutant) is distributed and transduces cells in the brain of a primate species closely related to humans when injected into the bloodstream or cerebrospinal fluids (CSF) Here we report a novel approach to generate three-dimensional (3D) vector transduction heat maps of more than one hundred of AAV strains in the rhesus monkey brain when vectors are delivered via the cisterna magna In this approach, we integrate the vector transduction data obtained by AAV Barcode-Seq (an Illumina sequencing-based high-throughput vector transduction analysis) into an MRI image To show proof-of-principle of the method, a barcoded-AAV library containing 145 different AAV strains was directly injected into CSF via the cisterna magna of three rhesus macaques (4x1012 vg/kg) and their brains were subjected to MRI analysis before collection of the organ 6 weeks post-injection Six mm-thick coronal sections of the brain were made and photographed, and the right half of each section slice was diced into
6 x 7 x 7 mm3 cubes using a matrix, generating more than 100 cubes from a cerebral hemisphere Total DNA was then extracted from each cube using an automated magnetic particle processor and subjected
to AAV Barcode-Seq analysis to determine transduction efficiency of each AAV strain in each cube by multiplexed Illumina sequencing The coordinates of each cube were determined by aligning the photo images of each coronal section to the corresponding MRI images using an image alignment algorithm This strategy allowed us to
Trang 2Molecular Therapy Volume 23, Supplement 1, May 2015 Copyright © The American Society of Gene & Cell Therapy
S190
Gene editinG and Gene ReGulation ii
create 3D heat maps showing distribution and transduction of each
AAV strain in the entire NHP brain A preliminary analysis using one
of the three monkeys revealed that AAV1 vector spreads globally and
transduces all brain regions including the cerebral cortex while the
distribution of AAV2 was limited locally Unexpectedly, we found
that many other serotypes and mutants transduced the NHP brain
better than AAV9 when delivered into CSF Thus, imaging of AAV
vector distribution and transduction throughout the NHP brain by AAV
Barcode-Seq combined with MRI provides a powerful approach to
comprehensively study AAV vector-mediated CNS gene delivery in
clinically relevant animal models Our results emphasize the large
difference in AAV distribution and transduction efficiency that exists
in the brain of higher primates compared to rodent models
478 Highly Efficient Targeted Gene Addition in
CD34+ Hematopoietic Stem/Progenitor Cells by
Combining ZFN mRNA and AAV6 Donor Delivery
Jianbin Wang,1 Colin M Exline,2 Josh DeClercq,1 Patrick Li,1
Philip D Gregory,1 Paula M Cannon,2 Michael C Holmes.1
1 Sangamo Biosciences Inc., Richmond, CA; 2 Molecular
Microbiology and Immunology, University of Southern California
Keck School of Medicine, Los Angeles, CA.
Zinc-finger nucleases (ZFNs) drive highly efficient genome editing
by generating a site-specific DNA double-strand break (DSB) at a
predetermined site in the genome Subsequent repair of this break
via the non-homologous end-joining (NHEJ) or homology-directed
repair (HDR) pathways results in targeted gene disruption or gene
correction/addition, respectively Hematopoietic stem/progenitor
cells (HSPC) are an important clinical target for gene therapy These
cells can be readily harvested from the subject, engineered using viral
vectors, and re-introduced back into the patient where they give rise
to all of the mature cells of the blood and immune system Thus the
ability to edit the genome of HSPCs could provide a corrective therapy
for a number of monogenic diseases However, achieving high levels
of editing by HDR may be significantly more challenging than gene
knockout by NHEJ Here we report that the combination of delivering
the ZFNs as mRNA and corrective donor DNA via a rAAV6 vector
can induce highly efficient targeted gene addition in CD34+ HSPCs
Using CCR5-specific ZFNs and donor DNA templates as a model
system we show that targeted addition of a novel restriction fragment
length polymorphism (RFLP) was consistently achieved at >15%,
while insertion of an eGFP expression cassette was achieved at >10%
of the CCR5 loci in mobilized CD34+ cells Furthermore, targeting
the AAVS1 “safe harbor” locus with a pair of AAVS1-specific ZFNs
(mRNA) and a RFLP donor (rAAV6) resulted in >30% of AAVS1
alleles specifically being edited to include the RFLP, suggesting this
genome editing approach to achieve highly efficient targeted gene
addition in CD34+ cells can be applied to different genetic loci Edited
HSPC undergo normal hematopoiesis in both in vitro differentiation
assays and during engraftment of NSG mice Using fetal liver derived
cells, editing of primitive and more committed CD34+ HSPC subsets
was observed at similar levels in HSPC CFU cultures, and by analysis
of sorted populations of treated HSPC, including LT-HSC, and
through the secondary transplantation of NSG mice
The use of ZFNs in combination with rAAV6 delivery of the donor
DNA provides a significant advance in genome editing that has great
potential for targeted correction of human disease-causing mutations
and permanent transgene addition in human CD34+ HSPC
Gene Editing and Gene Regulation II
479 ZFN-Mediated In Vivo Genome Editing Results in Supraphysiological Levels of Lysosomal Enzymes Deficient in Hunter and Hurler Syndrome and Gaucher Disease
Thomas Wechsler,1 Russel DeKelver,1 Michelle Rohde,1 Susan Tom,1 Scott Sproul,1 Leo Ou,2 Kanut Laoharawee,2 Kelly M Podetz-Pedersen,2 Chester B Whitley,2 Scott R McIvor,2 Philip D Gregory,1 Michael C Holmes.1
1 Sangamo BioSciences Inc., Richmond, CA; 2 Department of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, MN.
Lysosomal storage diseases (LSDs) represent a group of inherited metabolic disorders associated with mutations in genes encoding lysosomal enzymes leading to systemic accumulation of toxic storage materials Manifestations include organomegaly, skeletal dysplasias, cardiopulmonary obstruction, and severe neurologic impairment, often leading to death by age 10 Current LSD therapies include enzyme replacement therapy, substrate reduction therapy and hematopoietic stem cell transplant (HSCT) However, all of these therapies are expensive, incompletely effective, and HSCT is associated with significant risk of morbidity and mortality Due to the unmet need genome editing strategies are proposed to permanently modify patient cells by genetically complementing the LSD defect This is achieved by utilizing engineered zinc finger nucleases (ZFNs)
to introduce a DNA cut at the target locus, mediating integration of
a therapeutic LSD donor cDNA To ensure long-term expression of the transgenes in vivo we target the albumin locus as a “safe harbor”
in hepatocytes via co-delivery of the albumin ZFNs and LSD donors
by adeno-associated virus (AAV) This system exploits the high transcriptional activity of the native albumin enhancer/promoter; uses stably modified hepatocytes to potentially allow long-term expression of the inserted transgene; and utilizes an endogenous promoter obviating this requirement in the AAV payload We have previously exploited AAV-mediated in vivo targeting of the murine albumin “safe harbor” locus for the synthesis of therapeutic levels of FVIII and FIX to overcome the clotting defect in hemophilic mice Using the same approach, we co-delivered mouse albumin ZFNs with donor constructs encoding either human iduronate-2-sulfatase (IDS) deficient in Hunter syndrome, α-L-iduronidase (IDUA) for Hurler syndrome, or Glucocerebrosidase (GBA) for Gaucher disease via AAV in WT mice We show stable integration of the LSD donors
at the albumin locus, resulting in liver-specific expression and secretion of these proteins into plasma This led to a 4-fold (GBA), 10-fold (IDUA) or 100-fold (IDS) increase in enzymatic activity in the plasma, demonstrating that the secreted proteins are functional Importantly, increased activity was also detected in secondary tissues (spleen) showing efficient uptake and activity in distal tissues Moreover, preliminary data in MPSI and MPSII mice suggests these levels of IDS and IDUA expression may lead to correction of the enzyme deficiency IDS, IDUA and GBA expression remained stable throughout the study (up to 2 months), while expression of FIX has been stable for >1 yr suggesting this process results in long-term protein expression In summary, our data provide proof of concept for ZFN-mediated targeting of the albumin locus in hepatocytes as
an in vivo protein replacement platform to express different proteins associated with lysosomal storage diseases